Retatrutide
Retatrutide is currently aggressively evaluated as an incredibly novel phase-development triple agonist peptide. Current literature is radically investigating multi-receptor targeting focusing squarely upon massive combined systemic metabolic alterations.
Human ClinicalMetabolic ResearchEndocrine Research
Formula
Reported peptide-fatty acid conjugate (literature)
MW
≈4731 g/mol (literature)
Half-life
≈6 days (literature)
Studies
2
Research Material · Uptide.eu
View Research Material →Access product specifications, COA documentation and research material on Uptide.
Research overview
Retatrutide represents fully a completely novel extremely advanced experimental triple-hormone-receptor systemic agonist strategically engineered heavily targeting comprehensive simultaneous engagement of foundational GLP-1, GIP, alongside glucagon metabolic receptors. Clinical scientists aggressively study massive data evaluating extreme obesity reductions, widespread intricate bodyweight architectures, systemic glucose regulation systems, incredible resting aggregate energy expenditures, intense lipid panel shifts, specialized intrahepatic steatosis frameworks, alongside encompassing cardiometabolic arrays. Early-stage intense human phase 2 testing indicates unbelievably potent metabolic modifications compared fully via historical benchmarks, yet generalized medical status remains entirely absent. Information distinctly identifies retatrutide definitively traversing exclusively within highly restrictive evolving strictly pharmaceutical trial boundaries completely omitting general distribution claims.
Synonyms
LY3437943, GLP-1/GIP/Glucagon triagonist
Classification
Triple-hormone-receptor agonist
Molecular weight
≈4731 g/mol (literature)
Molecular formula
Reported peptide-fatty acid conjugate (literature)
CAS Number
2381089-83-2
Half-life
≈6 days (literature)
Evidence level
Human Clinical
Research areas
Metabolic Research, Endocrine Research
Pathways
GLP-1/GIP/Glucagon tri-agonist signalling, Hepatic lipid clearance mechanisms
Related compounds
Frequently co-cited in the literature
Research disclaimer
All information is provided for educational and scientific research purposes only. No content constitutes medical advice, treatment recommendations, administration guidance or dosing recommendations. Products referenced are intended for laboratory and analytical research.